ToFscan Monitor

Clinical Studies

Click on each title for the links

Operating Room

Intensive Care

2011

2021

2020

2017

2021

2002

2019

2017

2019

2. Neuromuscular monitoring and neuromuscular blocking agent shortages when treating critically ill COVID-19 patients: a multicentre retrospective analysis

Julia Ziatkowski-MichaudTessa MazardMarie-Charlotte DelignetteFlorent WalletFrederic AubrunMikhail Dziadzko

3. Technologies to Optimize the Care of Severe COVID-19 Patients for Health Care Providers Challenged by Limited Resources

Rubulotta, Francesca MD, PhD, MBA, FRCA, FICM; Soliman-Aboumarie, Hatem MD, FEACVI, FASE, FHEA; Filbey, Kevin MD; Geldner, Goetz MD, PhD; Kuck, Kai PhD; Ganau, Mario MD, PhD, FEBNS, FACS; Hemmerling, Thomas M. MSc, MD, DEAA

4. How to reduce cisatracurium consumption in ARDS patients: the TOF-ARDS study

Sami HraiechJean-Marie ForelChristophe GuervillyRomain RambaudSamuel LehingueMélanie AddaPierre SyllaSabine ValeraJulien CarvelliMarc GainnierLaurent PapazianJérémy Bourenne

5. Neuromuscular blockade management in patients with COVID-19

Harold Chaves-CardonaVivian Hernandez-TorresSean KileyJohnathan Renew

6. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients

Franck LagneauGilles D’honneurBenoît PlaudJean MantzThierry GillartPhilippe DuvaldestinJean MartyNathalie ClytiJean-Louis Pourriat

7. Current Use of Neuromuscular Blocking Agents in Intensive Care Units

Büşra TezcanSema TuranAyşegül Özgök

1. https://sfar.org/utilisation-des-curares-en-reanimation/

2. Neuromuscular monitoring and neuromuscular blocking agent shortages when treating critically ill COVID-19 patients: a multicentre retrospective analysis

Julia Ziatkowski-MichaudTessa MazardMarie-Charlotte DelignetteFlorent WalletFrederic AubrunMikhail Dziadzko

3. Technologies to Optimize the Care of Severe COVID-19 Patients for Health Care Providers Challenged by Limited Resources

Rubulotta, Francesca MD, PhD, MBA, FRCA, FICM; Soliman-Aboumarie, Hatem MD, FEACVI, FASE, FHEA; Filbey, Kevin MD; Geldner, Goetz MD, PhD; Kuck, Kai PhD; Ganau, Mario MD, PhD, FEBNS, FACS; Hemmerling, Thomas M. MSc, MD, DEAA

4. How to reduce cisatracurium consumption in ARDS patients: the TOF-ARDS study

Sami HraiechJean-Marie ForelChristophe GuervillyRomain RambaudSamuel LehingueMélanie AddaPierre SyllaSabine ValeraJulien CarvelliMarc GainnierLaurent PapazianJérémy Bourenne

5. Neuromuscular blockade management in patients with COVID-19

Harold Chaves-CardonaVivian Hernandez-TorresSean KileyJohnathan Renew

6. A comparison of two depths of prolonged neuromuscular blockade induced by cisatracurium in mechanically ventilated critically ill patients

Franck LagneauGilles D’honneurBenoît PlaudJean MantzThierry GillartPhilippe DuvaldestinJean MartyNathalie ClytiJean-Louis Pourriat

7. Current Use of Neuromuscular Blocking Agents in Intensive Care Units

Büşra TezcanSema TuranAyşegül Özgök